Arrowhead Pharmaceuticals, Inc. (ARWR) stock
ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Nov 12, 2026Score 5/3035% above fair value
$42.99−1.22 (-2.76%)
Close on Nov 17, 2026Market cap $6.07BP/E –Yield –
Arrowhead Pharmaceuticals total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Arrowhead Pharmaceuticals's total debt was $2.10M at Sep 30, 2018. For fiscal 2018 it was $2.10M, down 9.6% from the year before. The highest annual figure on record is $2.53M in fiscal 2016.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2018 | Sep 30, 2018 | $2.10M | -9.6% |
| FY2017 | Sep 30, 2017 | $2.33M | -8.2% |
| FY2016 | Sep 30, 2016 | $2.53M | +4966.9% |
| FY2013 | Sep 30, 2013 | $50.00K | -94.0% |
| FY2012 | Sep 30, 2012 | $839.42K | +38.3% |
| FY2011 | Sep 30, 2011 | $606.79K | – |
Quarterly total debt
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2018CQ3 2018 | Sep 30, 2018 | $2.10M | -9.6% |
| Q3 FY2018CQ2 2018 | Jun 30, 2018 | $2.16M | -9.2% |
| Q2 FY2018CQ1 2018 | Mar 31, 2018 | $2.22M | -8.9% |
| Q1 FY2018CQ4 2017 | Dec 31, 2017 | $2.27M | -8.5% |
| Q4 FY2017CQ3 2017 | Sep 30, 2017 | $2.33M | -8.2% |
| Q3 FY2017CQ2 2017 | Jun 30, 2017 | $2.38M | – |
| Q2 FY2017CQ1 2017 | Mar 31, 2017 | $2.43M | – |
| Q1 FY2017CQ4 2016 | Dec 31, 2016 | $2.48M | – |
| Q4 FY2016CQ3 2016 | Sep 30, 2016 | $2.53M | – |
See a number that looks wrong?